when it comes to special populations—such as elderly adults, pediatric patients, or those with renal or hepatic impairment—traditional paradigms may not apply. These groups often exhibit altered pharmacokinetics, higher safety risks, or disease-specific responses. Planning a FIH study in these populations requires thoughtful balancing of scientific need, ethics, regulatory compliance, and logistical feasibility. This guide explores how to strategically design Phase 1 trials for special populations and what considerations are essential for success.

Who Are Considered Special Populations in Clinical Trials?

• Elderly (typically >65 years)
• Pediatric patients (neonates to adolescents)
• Patients with renal or hepatic impairment
• Pregnant or lactating women (rare in FIH)
• Immunocompromised or genetically defined groups

Why Conduct FIH in Special Populations?

• Scientific necessity: The drug is unsafe or irrelevant in healthy adults
• Disease-driven pharmacology: PK/PD only meaningful in patient population
• Rare or ultra-rare indications: No viable healthy population to test on
• Regulatory flexibility: EMA/FDA may allow direct-to-patient FIH with proper justification

Key Planning Considerations

1. Risk-Benefit Assessment

• Ensure maximum preclinical data before proceeding
• Perform detailed exposure margin analysis and safety modeling

2. Justification for Excluding Healthy Volunteers

• Outline PK, immunogenicity, or disease-specific target engagement constraints
• Clearly justify in protocol and regulatory briefing documents

3. Dose Selection Strategy

• Use Minimum Anticipated Biological Effect Level (MABEL) for biologics
• Employ PBPK models incorporating age, renal clearance, enzyme maturation, etc.

4. Ethics and Informed Consent

• Must address capacity, comprehension, and parental consent where applicable
• Use audio-visual consent, teach-back, and translated materials

Study Design Approaches

1. Elderly-Only FIH Trials

• Common in Alzheimer’s, Parkinson’s, osteoporosis studies
• Stratify by frailty index or polypharmacy status

2. Pediatric Phase 1

• Start in adolescents (>12 years) before moving to younger age groups
• Use pediatric-specific formulations and palatability assessments
• Age de-escalation design preferred (adolescents → toddlers → neonates)

3. Renal and Hepatic Impairment Studies

• Use Child-Pugh or eGFR stratification
• Consider reduced sampling in severe impairment

4. Oncology and Rare Disease Populations

• Typical for first-in-class drugs targeting specific tumor types
• May include single-patient cohorts, basket trials, or expansion arms

Operational and Logistical Challenges

• Recruitment: Smaller pools, geographic limitations, caregiver dependency
• Consent process: Legal guardians, assent from minors, AV consent mandates (India)
• Comorbidities: More prevalent in elderly and pediatric populations
• Formulations: Require suspensions, chewables, or liquid forms

Regulatory Requirements

FDA

• Supports pediatric FIH only with strong preclinical and modeling data
• Renal and hepatic studies required before NDA if impaired populations are expected users

EMA

• Requires PIP (Pediatric Investigation Plan) before pediatric trials begin
• Allows adult-only Phase 1 with justification, but expects elderly inclusion in later phases

CDSCO

• Requires separate ethics and DCGI approval for pediatric and vulnerable populations
• Mandatory AV consent in FIH involving vulnerable groups

Safety Monitoring Enhancements

• Staggered enrollment and dosing
• Frequent safety labs, ECGs, telemetry
• Involve Data Safety Monitoring Boards (DSMB) with pediatric or geriatric specialists
• Build predefined stopping rules for organ dysfunction or unexpected AEs

Best Practices

• Start with robust modeling and simulation to guide dose and schedule
• Include adaptive design to allow cohort modification
• Use centralized screening for rare conditions or genetic markers
• Ensure cross-functional planning (clinical, regulatory, ethics, operations)
• Pre-engage advocacy groups or caregivers for community alignment